fingolimod hydrochloride has been researched along with Cognitive Decline in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 9 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X; Li, Y; Liu, X; Ren, Y; Weng, H | 1 |
| Arnatt, CK; Cuzzocrea, S; Doyle, TM; Esposito, E; Farr, SA; Green, M; Niehoff, ML; Salvemini, D; Spiegel, S; Squillace, S | 1 |
| Deng, W; Guo, W; Hu, X; Li, T; Ma, X; Ni, P; Qi, X; Wang, Q; Wei, L; Yu, X; Zhao, L | 1 |
| Cristiano, E; Pappolla, A; Patrucco, L; Rojas, JI; Sánchez, F | 1 |
| Fernandes, V; Khatri, DK; Khot, M; Preeti, K; Singh, SB; Sood, A | 1 |
| Altobelli, C; Anastasio, P; Barbarulo, AM; Conchiglia, G; D'Amico, A; Di Pietro, A; Fratta, M; Lus, G; Rossi, F; Signoriello, E; Ugga, L | 1 |
| Bürkner, PC; Hartung, HP; Holling, H; Johnen, A; Landmeyer, NC; Meuth, SG; Ruck, T; Wiendl, H | 1 |
| Conway, DS; Nakamura, K; Oh, SH; Ontaneda, D; Planchon, SM; Sakaie, K; Thompson, NR | 1 |
| Farbood, Y; Ghafouri, S; Najafian, SA; Sarkaki, A | 1 |
| Banu, MA; Berry, N; Boockvar, JA; Clausi, MG; Ryu, S; Stessin, AM | 1 |
| Fan, WH; Liu, Q; Murugan, M; Qin, C; Shang, K; Tian, DS; Wang, W; Wu, LJ | 1 |
| Ducruet, AF; Lawton, MT; Qiu, S; Sheth, KN; Shi, E; Shi, K | 1 |
1 review(s) available for fingolimod hydrochloride and Cognitive Decline
| Article | Year |
|---|---|
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
Topics: Cognition; Cognitive Dysfunction; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Randomized Controlled Trials as Topic | 2020 |
11 other study(ies) available for fingolimod hydrochloride and Cognitive Decline
| Article | Year |
|---|---|
Fingolimod loaded niosomes attenuates sevoflurane induced cognitive impairments.
Topics: Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Liposomes; Particle Size; Sevoflurane | 2021 |
Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment.
Topics: Animals; Central Nervous System; Cisplatin; Cognitive Dysfunction; Fingolimod Hydrochloride; Lysophospholipids; Mice; Mice, Inbred NOD; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2022 |
Fingolimod ameliorates schizophrenia-like cognitive impairments induced by phencyclidine in male rats.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Male; Phencyclidine; Rats; Rats, Sprague-Dawley; Schizophrenia | 2023 |
Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina.
Topics: Adult; Argentina; Biomarkers; Brain; Cognitive Dysfunction; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies | 2022 |
Fingolimod Alleviates Cognitive Deficit in Type 2 Diabetes by Promoting Microglial M2 Polarization via the pSTAT3-jmjd3 Axis.
Topics: Animals; Cell Polarity; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fingolimod Hydrochloride; Mice; Microglia; Neuroinflammatory Diseases; Signal Transduction | 2023 |
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis.
Topics: Adult; Alemtuzumab; Behavioral Symptoms; Brain Diseases; Brain Stem; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Mutism; Recurrence; White Matter; Young Adult | 2020 |
Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
Topics: Cognition; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Thalamus | 2021 |
FTY720 administration following hypoxia-induced neonatal seizure reverse cognitive impairments and severity of seizures in male and female adult rats: The role of inflammation.
Topics: Aging; Animals; Animals, Newborn; Cognitive Dysfunction; Epilepsy; Female; Fingolimod Hydrochloride; Hippocampus; Hypoxia; Inflammation; Male; Neuroprotective Agents; Pentylenetetrazole; Rats; Seizures; Severity of Illness Index | 2021 |
FTY720/fingolimod, an oral S1PR modulator, mitigates radiation induced cognitive deficits.
Topics: Animals; Brain Neoplasms; Cognition; Cognitive Dysfunction; Fingolimod Hydrochloride; Hippocampus; Mice, Inbred C57BL; Neural Stem Cells; Neurogenesis; Radiation Injuries; Radiotherapy; Receptors, Lysosphingolipid | 2017 |
Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway.
Topics: Animals; Brain Ischemia; Carotid Stenosis; Cell Polarity; Cognitive Dysfunction; Corpus Callosum; Cytokines; Fingolimod Hydrochloride; Macrophage Activation; Memory, Short-Term; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Ranvier's Nodes; Signal Transduction; STAT3 Transcription Factor; White Matter | 2017 |
Chronic inflammation, cognitive impairment, and distal brain region alteration following intracerebral hemorrhage.
Topics: Aminopyridines; Animals; Brain; Cerebral Hemorrhage; Cognition; Cognitive Dysfunction; Disease Models, Animal; Fingolimod Hydrochloride; Flow Cytometry; Hippocampus; Inflammation; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroimaging; Neuronal Plasticity; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2019 |